Literature DB >> 27986135

A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo.

Stefan G Vanderweil1, Shinya Amano1, Wei-Che Ko1, Jillian M Richmond1, Michelle Kelley1, Maryanne Makredes Senna1, Andrea Pearson1, Sandhya Chowdary1, Celia Hartigan1, Bruce Barton1, John E Harris2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27986135      PMCID： PMC5176345          DOI： 10.1016/j.jaad.2016.06.015

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  5 in total

1.  Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo.

Authors:  L Komen; V da Graça; A Wolkerstorfer; M A de Rie; C B Terwee; J P W van der Veen
Journal:  Br J Dermatol       Date:  2015-01-08       Impact factor: 9.302

2.  CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo.

Authors:  Mehdi Rashighi; Priti Agarwal; Jillian M Richmond; Tajie H Harris; Karen Dresser; Ming-Wan Su; Youwen Zhou; April Deng; Christopher A Hunter; Andrew D Luster; John E Harris
Journal:  Sci Transl Med       Date:  2014-02-12       Impact factor: 17.956

3.  Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita.

Authors:  Yiwei Zhao; Ulrike Gartner; Frances J D Smith; W H Irwin McLean
Journal:  J Invest Dermatol       Date:  2011-03-10       Impact factor: 8.551

4.  Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo.

Authors:  Priti Agarwal; Mehdi Rashighi; Kingsley I Essien; Jillian M Richmond; Louise Randall; Hamidreza Pazoki-Toroudi; Christopher A Hunter; John E Harris
Journal:  J Invest Dermatol       Date:  2014-12-18       Impact factor: 8.551

5.  Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo.

Authors:  Martin Noël; Claude Gagné; Jean Bergeron; Jean Jobin; Paul Poirier
Journal:  Lipids Health Dis       Date:  2004-05-10       Impact factor: 3.876
  5 in total
  6 in total

Review 1.  Vitiligo Pathogenesis and Emerging Treatments.

Authors:  Mehdi Rashighi; John E Harris
Journal:  Dermatol Clin       Date:  2017-04       Impact factor: 3.478

2.  Atorvastatin in Combination With Narrowband UV-B in Adult Patients With Active Vitiligo: A Randomized Clinical Trial.

Authors:  Sophie Nguyen; Sai Yee Chuah; Eric Fontas; Abdallah Khemis; Anjali Jhingan; Steven Tien Guan Thng; Thierry Passeron
Journal:  JAMA Dermatol       Date:  2018-06-01       Impact factor: 10.282

Review 3.  Vitiligo, From Physiopathology to Emerging Treatments: A Review.

Authors:  Laure Migayron; Katia Boniface; Julien Seneschal
Journal:  Dermatol Ther (Heidelb)       Date:  2020-09-19

Review 4.  Updates and new medical treatments for vitiligo (Review).

Authors:  David Emmanuel Kubelis-López; Natalia Aranza Zapata-Salazar; Salvador Luis Said-Fernández; Celia Nohemí Sánchez-Domínguez; Mauricio Andrés Salinas-Santander; Herminia Guadalupe Martínez-Rodríguez; Osvaldo Tomás Vázquez-Martínez; Uwe Wollina; Torello Lotti; Jorge Ocampo-Candiani
Journal:  Exp Ther Med       Date:  2021-05-25       Impact factor: 2.447

5.  The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial.

Authors:  Anna Niezgoda; Andrzej Winnicki; Tomasz Kosmalski; Bogna Kowaliszyn; Jerzy Krysiński; Rafał Czajkowski
Journal:  Trials       Date:  2019-01-25       Impact factor: 2.279

Review 6.  Research Progress on Targeted Antioxidant Therapy and Vitiligo.

Authors:  Jingzhan Zhang; Wen Hu; Peng Wang; Yuan Ding; Hongjuan Wang; Xiaojing Kang
Journal:  Oxid Med Cell Longev       Date:  2022-03-14       Impact factor: 6.543
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.